ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

perfluorohexyloctane

Also written as “NOV03”, “Miebo” and “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”.

Its studies are mostly in Dry Eye Syndromes, led by 2 companies.

Drug pagePerfluorohexyloctane: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 19, 202311 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies101 open or runningphase 4since Jan 19, 2023Oct 23, 2019none ahead
Novaliqits history only10 open or runningphase 2since Nov 2, 2017Nov 2, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bausch Health Companies only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2019First studies: 2 phase 3 studies in Dry Eye SyndromesFirst studyNCT04140227, NCT04139798
  2. Sep 23, 2020Phase 3 study in Dry Eye SyndromesNCT04567329 · 620 enrolled · United States
  3. Jan 19, 2023Phase 4 study in Dry Eye SyndromesNCT05723770 · 33 enrolled · United States
  4. Aug 6, 2023Named perfluorohexyloctaneINNProposed as its International Nonproprietary Name in WHO's List 129
  5. Mar 7, 20242 phase 4 studies in Dry Eye SyndromesNCT06309953, NCT06346340
  6. Aug 20, 2024Phase 4 study in Dry Eye SyndromesNCT06565650 · 216 enrolled · United States
  7. Jun 27, 2025Phase 4 study in Dry Eye SyndromesNCT07054606 · 104 enrolled · United States
  8. Aug 6, 2025Phase 2 study in Dry Eye SyndromesNCT07128628 · 443 enrolled · United States
  9. Aug 6, 2025Phase 3 study in Dry Eye SyndromesNCT07111013

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Bausch Health Companies leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07128628Dry Eye Syndromes · United States2CompletedMay 28, 2026443
NCT07111013Dry Eye Syndromes3WithdrawnApr 20270
NCT07054606Dry Eye Syndromes · United States4CompletedNov 3, 2025104
NCT06565650Dry Eye Syndromes · United States4Active, not recruitingNov 2025216
NCT06346340Dry Eye Syndromes · United States4CompletedFeb 24, 202597
NCT06309953Dry Eye Syndromes · United States4CompletedJun 17, 202499
NCT05723770Dry Eye Syndromes · United States4CompletedDec 23, 202333
NCT04567329Dry Eye Syndromes · United States3CompletedAug 30, 2021620
NCT04140227Dry Eye Syndromes · United States3CompletedJan 5, 2022256
NCT04139798Dry Eye Syndromes · United States3CompletedMar 12, 2021599

How it is read

Names in the registry

  • “NOV03”, 4 entries
  • “Miebo”, 3 entries
  • “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”, 1 entry
  • “Perfluorohexyloctane ophthalmic solution”, 1 entry
  • “Lifitegrast/perfluorohexyloctane (PFHO)”, 1 entry

Codes read as this program: NOV03.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.